Find disease awareness content and relevant supporting materials
Primary endpoint in phase III TRANQUILITY-2 trial in dry eye disease is achieved and plans are to submit a NDA for symptoms and three sign endpoints of dry eye disease.
Aldeyra Therapeutics, Inc. announced the achievement of the primary endpoint in the Phase III TRANQUILITY-2 clinical trial (TRANQUILITY-2) of reproxalap, an investigational new drug candidate, for the treatment of dry eye disease.
A Prospective, Randomized, Doubled-masked, Single Center, Clinical Comparison of Autologous Serum, Heterologous Serum and Umbilical Cord Serum Eye Drops in the Management of Dry Eye Syndrome
To valuate tear film and ocular surface changes after autologous serum therapy, heterologous serum therapy and umbilical cord therapy in...
Aldeyra announces first patient enrolled in the phase III TRANQUILITY trial of reproxalap for the treatment of dry eye disease.
Aldeyra Therapeutics, Inc. announced enrollment of the first patient in the Phase III TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease.